Saskatchewan Immunization Manual Amendments April 2023

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 7 Immunization of Special Populations

- Appendix 7.6: Publicly Funded Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant
  - COVID-19 booster dose changed to 6 months interval to align with provincial recommendations.
- Recipients Appendix 7.8: Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations
  - Added as footnote #2A: Screen adults and children from countries where the seroprevalence of chronic HB infection is ≥2% for all 3 markers (Pottie et al., 2011).

Chapter 8 Administration of Biological Products

- TOC Appendix 8.2 renamed Potentially Immunosuppressive Biologic Agents
- P. 33 Appendix 8.2 renamed Potentially Immunosuppressive Biologic Agents

Chapter 10 Biological Products

- TOC addition
  - New vaccine added! PREHEVBRIO™ 3-antigen Hepatitis B Vaccine (recombinant)
- Novavax Nuvaxovid 12+ **Monovalent** formulation
  - Product monograph date updated.
  - Storage and Handling:
    - Time for use after first vial puncture increased to 12 hours from 6 hours
    - Time out of Refrigeration (ToR) in syringe increased to 12 h from 6 hours
- Pfizer Comirnaty monovalent vaccines (6 mo-4 yrs, 5-11 years and 12+)
  - Product monograph dates updated.
  - Possible Reactions
    - Deleted:
      - ~~Bell's Palsy has been reported post-immunization in adults but is considered a rare event.~~
      - ~~Paresthesia, hypothesia and erythema multiforme are noted in the product monograph.~~
    - Added:
      - Facial paralysis / Bell's Palsy, hypoesthesia, paresthesia, dizziness, skin rash, pruritus, urticaria, angioedema, erythema multiforme and pain in extremity (arm) reported as post-market adverse events.
  - Added under Precautions:
    - Very rare cases of myocarditis and/or pericarditis following vaccination with COMIRNATY have been reported during post-authorization use. These cases occurred more commonly after the second dose and in adolescents and young adults. Typically, the onset of symptoms has been within a few days following receipt of COMIRNATY. Based on accumulating data, the reporting rates of myocarditis and pericarditis after COMIRNATY primary series in children ages 5 through <12 years are lower than in ages 12 through 17 years. Available short-term follow-up data suggest that the symptoms resolve in most individuals, but information on long-term sequelae is lacking. The decision to administer COMIRNATY to an individual with a history of myocarditis or pericarditis should take into account the individual's clinical circumstances.

Saskatchewan Immunization Manual Amendments April 2023

- New! PREHEVBRIO™ 3-antigen Hepatitis B Vaccine (recombinant)
    - This HB vaccine is only available on private market at this time.